GSK plc 6-K, filed Sep 25, 2023
GSK plc (GSK)
6-K
2023-09-25
For: 2023-09-25
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on September 25, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of September 2023
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 25 September 2023, London UK
Japan's Ministry of Health, Labour and
Welfare approves GSK's Arexvy, the country's first respiratory syncytial virus
(RSV) vaccine for older adults
●
Arexvy's approval
will help protect adults 60 years of age and older in Japan from
RSV disease for
the first time, including those living with underlying medical
conditions who are most at risk of severe RSV
disease
● RSV causes an estimated 63,000 hospitalisations
and 4,500 in-hospital deaths in adults 60 years of age and older in
Japan each year
● The approval - the first in Asia - is based on a
comprehensive phase III programme, which enrolled over 1,000
Japanese participants
GSK plc (LSE/NYSE: GSK) today announced that Japan's Ministry of
Health, Labour and Welfare (MHLW) has
approved Arexvy (respiratory syncytial virus vaccine,
recombinant adjuvanted) for the prevention of RSV (respiratory
syncytial virus) disease for adults 60 years of age and above. This
is the first time an RSV vaccine for older adults has been approved
in Japan.
Tony Wood, Chief Scientific Officer at GSK, said:
"Arexvy is Japan's first approved RSV older adult
vaccine, and is a major advance for public health with the
potential to help protect around 43.5 million Japanese people aged
60 and older[1].
Following key approvals in the US, EU, UK and Canada earlier this
year, today's authorisation reinforces GSK's industry-leading
vaccine portfolio".
RSV is a common, contagious respiratory virus[2] that
causes an estimated 470,000 hospitalisations and 33,000 deaths each
year in adults 60 years of age and older in industrialised
countries, including approximately 63,000 hospitalisations and
4,500 deaths in Japan.[3] Its
impact on healthcare systems may further increase as the population
ages. Those with underlying medical conditions, such as chronic
heart disease, chronic lung disease or diabetes, account for the
majority of RSV hospitalisations.[4]
The approval has been granted based on data from the pivotal
AReSVi-006 (Adult Respiratory Syncytial Virus) phase III vaccine
efficacy trial, published in the New England Journal of
Medicine (https://www.nejm.org/doi/full/10.1056/NEJMoa2209604).
In the trial, the vaccine showed statistically significant and
clinically meaningful overall efficacy of 82.6% (96.95% CI,
57.9-94.1, 7 of 12,466 in the Arexvy arm vs 40 of 12,494 in the placebo arm)
against RSV-LRTD in adults aged 60 years and older, meeting the
primary endpoint. In addition, secondary descriptive endpoints show
that efficacy was 94.6% (95% CI, 65.9-99.9, 1 of 4,937 in the
Arexvy arm vs 18 of 4,861 in the placebo arm) in older adults with
at least one underlying medical condition of interest, such as
certain cardiorespiratory and endocrine-metabolic
conditions.[5]
The vaccine was generally well tolerated. The most frequently
observed solicited adverse events were injection site pain,
fatigue, myalgia, headache and arthralgia. These were generally
mild to moderate and transient.
This is the fifth major regulatory approval
for Arexvy, building on approvals from the US Food and Drug
Administration (https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-gsk-s-arexvy-the-world-s-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/),
the European Commission (https://www.gsk.com/en-gb/media/press-releases/european-commission-authorises-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/),
and the regulatory authorities in the UK and
Canada.
About Arexvy
Respiratory syncytial virus vaccine, adjuvanted,
contains recombinant glycoprotein F stabilised in the prefusion
conformation (RSVPreF3). This antigen is combined with GSK's
proprietary AS01E adjuvant.
The MHLW has approved Arexvy for the prevention of RSV (respiratory
syncytial virus) disease for adults aged 60 years and above. The
use of this vaccine should be in accordance with official
recommendations. As with any vaccine, a protective immune response
may not be elicited in all vaccinees.
Arexvy, the trade name approved
in the US, EU/EEA, UK, Canada and Japan, remains subject to
regulatory approval in other markets.
The GSK proprietary AS01 adjuvant system contains STIMULON QS-21
adjuvant licensed from Antigenics Inc, a wholly owned subsidiary of
Agenus Inc. STIMULON is a trademark of SaponiQx Inc., a subsidiary
of Agenus.
About AReSVi-006
This is a randomised, placebo-controlled, observer-blind,
multi-country phase III trial to demonstrate the efficacy of a
single dose of GSK's adjuvanted RSVPreF3 vaccine in adults aged 60
years and above. Approximately 25,000 participants were enrolled
from 17 countries. Initial results were published in
the New England Journal of
Medicine in February
2023.
About respiratory syncytial virus (RSV) in adults
RSV is a common contagious virus affecting the lungs and breathing
passages. Older adults are at high risk for severe disease. RSV can
exacerbate conditions, including chronic obstructive pulmonary
disease (COPD), asthma and chronic heart failure and can lead to
severe outcomes, such as pneumonia, hospitalisation, and death.
Each year, RSV causes over 470,000 hospitalisations and 33,000
in-hospital deaths in adults 60 years of age and older in
industrialised countries, including approximately 63,000
hospitalisations and 4,500 deaths in Japan. Adults with underlying
conditions are more likely to seek medical advice and have higher
hospitalisation rates than adults without these
conditions.
Please refer to the updated Product Information (PI) for important
dosage, administration, and safety information in Japan which will
shortly be updated at this link: https://www.info.pmda.go.jp/psearch/html/menu_tenpu_base.html
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Simon
Moore
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Alison
Hunt
|
+1 540 742 3391
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Camilla
Campbell
|
+44 (0)
7803 050238
|
(London)
|
|
|
Steph
Mountifield
|
+44 (0)
7796 707505
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors" in the company's Annual Report on Form 20-F for
2022, and Q2 Results for 2023 and any impacts of the COVID-19
pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
References
[1] Statistics Bureau Home
Page/Population Estimates Monthly Report (https://www.stat.go.jp/english/data/jinsui/tsuki/index.html)
[2] Centers for Disease
Control and Prevention. RSV in Older Adults and Adults with Chronic
Medical Conditions. Accessed March 2023. Available
at: cdc.gov/rsv/high-risk/older-adults.html
[3] Savic M et al.,
"Respiratory syncytial virus disease burden in adults aged
60 years and older in high-income countries: A systematic
literature review and meta-analysis", in Influenza Other Respir
Viruses 2023;17(1):e13031.
doi.org/10.1111/irv.13031
[4] Tseng HF, Sy LS,
Ackerson B, et al., "Severe morbidity and short- and mid- to
long-term mortality in older adults hospitalized with respiratory
syncytial virus infection" in J Infect
Dis. 2020;222(8):1298-1310.
doi:10.1093/infdis/jiaa361
[5] The New England Journal of
Medicine, Respiratory Syncytial
Virus Prefusion F Protein Vaccine in Older
Adults https://www.nejm.org/doi/10.1056/NEJMoa2209604
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: September
25, 2023
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|